Vyome Holdings, Inc. Annual Report Summary: Fiscal Year Ended December 31, 2025

This summary offers a concise look at Vyome Holdings, Inc.'s performance and strategic direction for the fiscal year ended December 31, 2025, drawing directly from their annual report.

Business Overview

Vyome Holdings, Inc. is a clinical-stage specialty pharmaceutical company dedicated to developing innovative treatments for immune-inflammatory and rare diseases where patient needs are currently unmet. As a "clinical-stage" company, Vyome primarily focuses on researching and testing new drug candidates in human trials, rather than selling approved products from its biotechnology segment.

A pivotal corporate event occurred on August 15, 2025, when ReShape Lifesciences Inc. completed a reverse merger with Vyome Therapeutics, Inc., subsequently adopting the new name Vyome Holdings, Inc. This strategic maneuver allowed Vyome Therapeutics to become a publicly traded entity. The company maintains operations across Cambridge, MA, Princeton, NJ, and New Delhi, India, strategically leveraging its "US-India innovation corridor" for advantages in research, development, and cost efficiency.

Vyome operates through two distinct segments:

1. Biotechnology: This segment focuses on discovering and developing new drug candidates. As of this reporting period, it has not generated product sales revenue, reflecting its primary focus on advancing its research and development pipeline.
2. Pharmaceutical Products: This segment represents a legacy business, primarily from the former Vyome Therapeutics. It generates revenue through licensing agreements for commercialized anti-fungal products in India.

Financial Performance

As a clinical-stage company, Vyome's financial profile clearly shows significant investment in research and development, with limited product sales revenue from its biotechnology segment.

• Revenue (FY2025): Approximately $1.5 million, primarily from pharmaceutical segment licensing fees. This marks a decrease from $1.8 million in FY2024. The decline stems from a strategic shift in the commercial arrangement with Sun Pharma, moving from direct product sales to a net service fee model.
• Net Loss (FY2025): Approximately $(12.5 million), an increase from $(10.2 million) in FY2024. This expanded net loss primarily resulted from increased research and development expenditures as the company advanced its pipeline.
• Research & Development (R&D) Expenses (FY2025): Approximately $8.0 million, up from $6.5 million in FY2024. This increase reflects pipeline advancement, particularly the progression of VT-1953 into Phase 2 and the initiation of pre-clinical studies for VT-1908.
• General & Administrative (G&A) Expenses (FY2025): Approximately $4.0 million, consistent with the prior year. This indicates stable overhead costs despite the corporate transformation.

Risk Factors

Investing in a clinical-stage pharmaceutical company like Vyome involves substantial risks:

• Clinical Trial and Regulatory Risks: Drug development is inherently uncertain. There is no guarantee that VT-1953, VT-1908, VB-1953, or any other pipeline candidate will successfully complete clinical trials, demonstrate efficacy and safety, or receive regulatory approvals from bodies like the FDA. Delays in trials, patient recruitment, or regulatory processes are common, significantly increasing costs and postponing potential revenue generation.
• Funding and Liquidity Risk: Vyome has incurred significant losses and will require substantial additional capital to fund its operations and advance its drug candidates, as highlighted by a "going concern" warning. This warning indicates that the company's current financial resources may not be sufficient to continue operations for the next 12 months. There is no assurance that adequate financing will be available on favorable terms, or at all, which could force the company to delay or abandon development programs.
• Competition: Even if a drug gains approval, it may face intense competition from existing treatments or other pipeline candidates from larger, more established pharmaceutical companies with greater resources. Market acceptance is not guaranteed.
• Intellectual Property (IP) Protection: Vyome's success depends on its ability to protect its intellectual property. Challenges to patents or the inability to secure new patents could severely impact its commercial prospects.
• Reverse Merger Integration and Dilution: The recent reverse merger may present integration challenges. Future capital raises, often necessary for clinical-stage biotechs, could lead to significant dilution for existing shareholders.
• Dependence on Key Personnel and Partnerships: The company's success relies heavily on its scientific and management teams, as well as strategic partnerships like the one with Sun Pharma. The loss of key personnel or disruption to these partnerships could negatively impact operations.
• Forward-Looking Statements: The company's report contains "forward-looking statements" regarding future plans and expectations. Investors should be aware that actual results could differ materially due to various risks and uncertainties.

Management Discussion and Analysis (MD&A) Highlights

Fiscal year 2025 saw significant progress in advancing Vyome's drug pipeline and refining commercial strategies, with clear financial implications.

Results of Operations

• Revenue: Revenue decreased from $1.8 million in FY2024 to $1.5 million in FY2025. This change reflects a strategic shift in the Pharmaceutical Products segment: the company transitioned from direct product sales to a net service fee model with Sun Pharma. While this reduced operational overhead and inventory risk, it resulted in a lower top-line revenue figure for the period.
• Research and Development (R&D) Expenses: R&D expenses increased from $6.5 million to $8.0 million, demonstrating the company's commitment to advancing its clinical pipeline. This increase primarily stemmed from positive Phase 2 trial results for VT-1953 and subsequent planning for Phase 3, along with ongoing pre-clinical work for VT-1908. Management views these investments as crucial for long-term value creation.
• General and Administrative (G&A) Expenses: G&A expenses remained consistent at approximately $4.0 million. This stability highlights management's efforts to control administrative costs, even amidst the corporate transformation following the reverse merger.
• Net Loss: The net loss expanded to $(12.5 million) in FY2025, compared to $(10.2 million) in FY2024. This directly resulted from the increased R&D investment, a common characteristic of clinical-stage biotechnology companies focused on pipeline development rather than immediate commercialization.

Liquidity and Capital Resources

• Cash Position: As of December 31, 2025, the company held approximately $5.0 million in cash and cash equivalents.
• Working Capital: A working capital deficit of approximately $(2.0 million) as of December 31, 2025, indicates a short-term liquidity challenge.
• Going Concern: The company's financial statements include a "going concern" warning. This means current cash resources may not be sufficient to fund operations for the next 12 months without additional financing. Management acknowledges the need to raise additional capital to support ongoing research and development activities, fund potential Phase 3 trials, and cover general operating expenses. There is no guarantee that such financing will be available on acceptable terms, or at all.
• Market Value and Shares Outstanding: As of June 30, 2025, the aggregate market value of common stock held by non-affiliates was approximately $6.4 million. As of March 17, 2026, 7,018,528 shares of common stock were outstanding.
• Company Classification: Vyome identifies as a "non-accelerated filer," a "smaller reporting company," and an "emerging growth company." These designations allow for reduced reporting requirements and certain exemptions from Sarbanes-Oxley provisions, which can help manage administrative costs but also signal a higher-risk investment profile.

Financial Health

Vyome's financial health is defined by significant R&D investment, leading to recurring net losses, and a reliance on external financing for continued operations. The cash balance of approximately $5.0 million and a working capital deficit of $(2.0 million) as of December 31, 2025, underscore a constrained liquidity position. The explicit "going concern" warning highlights the company's need to secure additional capital within the next 12 months to sustain its operations and advance its pipeline. Overall financial stability depends on successful capital raises.

Future Outlook

Vyome's strategy centers on efficient drug development and leveraging its unique operational model:

• Accelerated VT-1953 Development: The company plans to aggressively advance VT-1953 into a pivotal Phase 3 study for Malignant Fungating Wounds (MFW). They anticipate a relatively short trial duration (with symptoms potentially resolving within 14 days) and intend to utilize their US-India network to expedite patient recruitment and manage costs effectively. Engagement with the FDA is planned for the first half of 2026 to finalize the Phase 3 design.
• "Smart Drug Development" Approach: Vyome focuses on:
  • Rare and Unmet Medical Needs: Targeting conditions with limited existing treatments.
  • Drug Repurposing: Often adapting existing, FDA-approved active pharmaceutical ingredients for new indications. This strategy aims to save time (by avoiding de novo drug discovery), reduce risk (by leveraging known safety profiles), and potentially qualify for Orphan Drug Act benefits (incentives, market exclusivity, and faster review for drugs treating rare diseases), while also requiring fewer patients for clinical trials, thereby lowering costs.
• Leveraging the US-India Corridor: The company emphasizes its strong presence and connections in both the US and India to identify new business and investment opportunities, optimize operational costs, and foster strategic partnerships. This "US-India corridor" is considered a significant competitive advantage, particularly amidst global geopolitical shifts.
• Pipeline Advancement: Beyond VT-1953, the company plans to initiate human trials for VT-1908 by the second half of 2025 and is evaluating strategic options for advancing VB-1953 into Phase 3.

Competitive Position

Vyome operates in highly competitive therapeutic areas, facing both established pharmaceutical companies and emerging biotechs.

• Malignant Fungating Wounds (MFW): For VT-1953, the competitive landscape for MFW (severe, often cancerous, wounds) lacks specific FDA-approved treatments. Current management often involves palliative care, wound dressings, and off-label use of antibiotics or antifungals. Vyome aims to differentiate VT-1953 by seeking orphan drug designation and providing a targeted, effective treatment for a condition with significant unmet needs.
• Immune-Inflammatory Eye Conditions (e.g., Anterior Uveitis): VT-1908 will compete with existing steroid-based treatments and other emerging therapies. Vyome's strategy targets patients where steroids are unsuitable or ineffective, leveraging its potential orphan drug status and novel mechanism of action.
• Acne: For VB-1953, the acne market is crowded with numerous topical and systemic treatments, including generics, branded products, and new formulations from large pharmaceutical companies. Differentiation will rely on demonstrating superior efficacy, safety, or a unique patient profile for moderate to severe acne.
• Overall Competitive Advantages: Vyome seeks to gain a competitive edge through its "Smart Drug Development" approach, focusing on drug repurposing for rare diseases to accelerate development, reduce risk, and leverage regulatory incentives. Its "US-India innovation corridor" model is also positioned as a strategic advantage for cost-effective R&D and access to diverse talent and markets. However, larger competitors typically possess greater financial, technical, and human resources, and more extensive experience in clinical development, regulatory affairs, manufacturing, and marketing.